Findings of the enrichment analysis of hotspot mutations and CNVs per tumor type are in line with published data (APC, KRAS, and SMAD4 mutations in CRC; TP53 and CCNE1 in ovarian cancer; PIK3CA and ESR1 in breast cancer; and CDK4 in sarcoma [Fig. 2]). This evidence concerns the gene CDK4 and neoplasm.